相关产品推荐更多 >
万千商家帮你免费找货
0 人在求购买到急需产品
- 详细信息
- 询价记录
- 文献和实验
- 技术资料
- 英文名:
ODN 2006 (ODN 7909)
- 供应商:
研卉生物
- 规格:
200 ug
ynonyms: ODN 7909, PF_3512676
Specificity: human TLR9 agonist
Working concentration: 5 µM (10 μg/ml)
Solubility: 5 mg/ml in water
ODN 2006 sequence
5’-tcgtcgttttgtcgttttgtcgtt-3’ (24 mer)
Note: Bases are phosphorothioate (nuclease resistant).
CpG ODNs are synthetic oligonucleotides that contain unmethylated CpG dinucleotides in particular sequence contexts (CpG motifs) [1]. These CpG motifs are present at a 20-fold greater frequency in bacterial DNA compared to mammalian DNA. CpG ODNs are recognized by Toll-like receptor 9 (TLR9) leading to strong immunostimulatory effects [2].
Three types of stimulatory CpG ODNs have been identified, types A, B and C, which differ in their immune-stimulatory activities [3-4]. Type A CpG ODNs are characterized by a phosphodiester central CpG-containing palindromic motif and a phosphorothioate 3’ poly-G string. They induce high IFN-α production from plasmacytoid dendritic cells (pDC) but are weak stimulators of TLR9-dependent NF-κB signaling. Type B CpG ODNs contain a full phosphorothioate backbone with one or more CpG dinucleotides. They strongly activate B cells but stimulate weakly IFN-α secretion. Type C CpG ODNs combine features of both types A and B. They contain a complete phosphorothioate backbone and a CpG-containing palindromic motif. Type C CpG ODNs induce strong IFN-α production from pDC and B cell stimulation.
ODN 2006 is a CpG ODN type B specific for human TLR9.
1. Krieg, A.M. et al., 1995. CpG motifs in bacterial DNA trigger direct B-cell activation. Nature, 374(6522):546-9.
2. Bauer, S. et al., 2001. Human TLR9 confers responsiveness to bacterial DNA via species-specific CpG motif recognition. PNAS. 98(16):9237-42.
3. Krug A. et al., 2001. Identification of CpG oligonucleotide sequences with high induction of IFN- alpha/beta in plasmacytoid dendritic cells. Eur J Immunol, 31(7): 2154-63.
4. Marshall JD. et al., 2005. Superior activity of the type C class of ISS in vitro and in vivo across multiple species. DNA Cell Biol. 24(2):63-72.
ODN 2006 (ODN 7909) | Cat. # : tlrl-2006
TLR9 Agonist - Stimulatory CpG ODN, Class B, Human preferred
ODN 2006 control (ODN 2137) | Cat. # : tlrl-2006c-5
ODN 2137 : Negative control for ODN 2006
ODN 2006-G5 | Cat. # : tlrl-2006g5-1
TLR9 Agonist - Stimulatory CpG ODN, Class B, Human preferred
ODN 2006-G5 | Cat. # : tlrl-2006g5-5
TLR9 Agonist - Stimulatory CpG ODN, Class B, Human preferred
ODN 2006 Biotin | Cat. # : tlrl-2006b
TLR9 Agonist - Biotin-labelled CpG ODN 2006, Class B, Human preferred
ODN 2006 control (ODN 2137) | Cat. # : tlrl-2006c-1
ODN 2137 : Negative control for ODN 2006
ODN 2006 (ODN 7909) | Cat. # : tlrl-2006-5
TLR9 Agonist - Stimulatory CpG ODN, Class B, Human preferred
ODN 2006 control (ODN 2137) | Cat. # : tlrl-2006c
ODN 2137 : Negative control for ODN 2006
ODN 2006-G5 | Cat. # : tlrl-2006g5
TLR9 Agonist - Stimulatory CpG ODN, Class B, Human preferred
ODN 2006 FITC | Cat. # : tlrl-2006f
TLR9 Agonist - FITC-labelled CpG ODN 2006, Class B, Human preferred
ODN 2006 (ODN 7909) | Cat. # : tlrl-2006-1
TLR9 Agonist - Stimulatory CpG ODN, Class B, Human preferred
ODN 2006-G5 control | Cat. # : tlrl-2006g5c
Negative control for ODN 2006-G5
风险提示:丁香通仅作为第三方平台,为商家信息发布提供平台空间。用户咨询产品时请注意保护个人信息及财产安全,合理判断,谨慎选购商品,商家和用户对交易行为负责。对于医疗器械类产品,请先查证核实企业经营资质和医疗器械产品注册证情况。
- 作者
- 内容
- 询问日期
文献和实验Antisense Efficacy: Site-Restricted In Vivo and Ex Vivo Models
In the laboratory, antisense oligodeoxynucleotides (ODN) have repeatedly demonstrated efficacy in modulating the expression of various genes, thus providing important insights into their roles in tumorigenesis or normal growth and development
Modulation of human interferon- biosynthesis by antisense oligodeoxynucleotides
We investigated the inhibition of human interferon-γ (HuIFN-γ) production in cultures of lymphocytes with the use of the antisense strategy. Out of a series of antisense oligodeoxynucleotides (ODN) complementary to different regions of the HuIFN
Transport of Antisense Across the Blood-Brain Barrier
. Recently, two types of unmodified antisense analogs have been shown to effectively cross the BBB and affect CNS function. One of the analogs, a phosphorothioate oligodeoxy-nucleotide (P-ODN) directed against the amyloid β protein, was peripherally
技术资料暂无技术资料 索取技术资料







